1. What the law is
The only psilocybin language Minnesota enacted in 2026 is buried in a cannabis act. Section 116 of Minnesota Laws 2026, chapter 123 orders the Office of Cannabis Management to publish a report by January 15, 2027 on how a psilocybin therapeutic use program could be administered for adults 21 and older with qualifying conditions. A report duty is not access. None of the five bills that would have gone further has passed: HF 2699 and HF 2906, introduced in 2025, and HF 4577, SF 4204 and SF 4485, which stalled in committee before the session adjourned in May 2026. The state's Psychedelic Medicine Task Force had recommended decriminalization and a regulated therapeutic program in its final report of January 2025.
Psilocybin remains illegal under Minnesota law, where it is listed as a Schedule I controlled substance; possession, cultivation, and sale carry criminal penalties statewide. Minnesota has nonetheless followed a deliberate study-first path. The 2023 health omnibus bill established a Psychedelic Medicine Task Force to examine the legal, medical, and policy questions raised by psilocybin, MDMA, and LSD. The task force delivered its final report to the legislature in January 2025, recommending decriminalization of psilocybin and creation of a regulated therapeutic program. Legislation followed within months. HF 2699, introduced in March 2025, would remove criminal penalties for personal use and home cultivation by adults 21 and older. HF 2906, introduced the same month with companion SF 3971, would create a psilocybin therapeutic use program: access limited to adults 21 and older with qualifying conditions, 20 to 50 licensed facilitators at launch, a 1,000-patient cap for the first three years, oversight shared by the Department of Health and the Office of Cannabis Management, and reclassification of psilocybin from Schedule I to Schedule IV. HF 2906 cleared the House Health Finance and Policy Committee on a bipartisan voice vote on March 16, 2026, and was re-referred to the Commerce Finance and Policy Committee. As of June 2026, neither bill has passed either chamber.
Minnesota offers the cleanest current example of the study-first legislative pattern: a statutorily created task force, a formal report to the legislature, and bills drafted to track its recommendations, rather than legislation arriving ahead of the evidence review. The bipartisan committee approval of HF 2906 in March 2026 distinguishes it from the many therapeutic-use bills that stall without a hearing. What stands between the current posture and enactment remains substantial: passage through the Commerce committee, floor votes in both chambers, and the governor's signature. The near-term question is whether HF 2906 reaches a floor vote before the session ends; as of June 2026 it has not.
2. Trials in Minnesota
Interventional psilocybin trials with at least one site in Minnesota, as their sponsors filed them with ClinicalTrials.gov, EU CTIS and ISRCTN. Each row links to the registry record, which sets out who may take part.
Recruiting or opening counts trials recruiting now, not yet recruiting, or enrolling by invitation. Closed counts trials terminated, suspended, withdrawn or left unverified by their sponsors.
| Registry ID | Trial | Phase | Sponsor | Status | Start date |
|---|---|---|---|---|---|
| NCT06793397 | A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder (opens in new tab)Recruiting at Institute for Integrative Therapies, Eden Prairie | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Recruiting | Start date |
| NCT07833761 | ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder (opens in new tab)Sites in Minneapolis and Saint Louis Park | Phase Phase 1 | Sponsor University of Minnesota | Status Not yet recruiting | Start date |
| NCT06605105 | Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) (opens in new tab)Site at Institute for Integrative Therapies, Eden Prairie | Phase Phase 3 | Sponsor Cybin IRL Limited | Status Enrolling by invitation | Start date |
| NCT05711940 | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD (opens in new tab)Site at Institute for Integrative Therapies, Eden Prairie | Phase Phase 3 | Sponsor COMPASS Pathways | Status Active, not recruiting | Start date |
| NCT05624268 | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD (opens in new tab)Site at University of Minnesota, Minneapolis | Phase Phase 3 | Sponsor COMPASS Pathways | Status Completed | Start date |
| NCT04424225 | Visual Surround Suppression and Perceptual Expectation Under Psilocybin (opens in new tab)Site at University of Minnesota, Minneapolis | Phase Phase 1 | Sponsor University of Minnesota | Status Terminated | Start date |
ClinicalTrials.gov data courtesy of the U.S. National Library of Medicine.
3. History
The legal events behind this entry, dated and oldest first. Our own reviews and corrections are listed under Changes to this record.
Governor Tim Walz signs the health omnibus bill (SF 2995), establishing the Psychedelic Medicine Task Force to study the legal, medical, and policy issues around psilocybin, MDMA, and LSD.
The Psychedelic Medicine Task Force submits its final legislative report, recommending psilocybin decriminalization and a state-regulated therapeutic program.
HF 2699 is introduced in the House, proposing to remove criminal penalties for psilocybin possession, cultivation, and personal use by adults 21 and older.
HF 2906 is introduced in the House, proposing a regulated psilocybin therapeutic use program and reclassification of psilocybin from Schedule I to Schedule IV.
The House Health Finance and Policy Committee approves HF 2906 as amended on a bipartisan voice vote and re-refers it to the Commerce Finance and Policy Committee.
Most recent recorded action on HF 2906: an additional author is added. The bill remains in committee, not yet passed by either chamber.
4. Proposed laws
Proposals that are not yet law and would change this entry if adopted.
HF 2906 / companion SF 3971: psilocybin therapeutic use program (21+, qualifying conditions, 20-50 licensed facilitators, 1,000-patient cap for first 3 years, MDH + Office of Cannabis Management oversight). Committee report to adopt as amended, re-referred to Commerce Finance and Policy Mar 16, 2026; last recorded action Apr 22, 2026 (author added). Three further 2026 vehicles stalled in committee: HF 4577 (recalled and re-referred to Veterans and Military Affairs Division Apr 9, 2026), SF 4485 (Senate Health and Human Services, Mar 17, 2026) and SF 4204, companion to HF 2699 (Judiciary and Public Safety, Mar 9, 2026). None passed either chamber; the 2026 regular session adjourned May 18, 2026.
5. Common questions
Is psilocybin legal in Minnesota?
Psilocybin has mixed legal status in Minnesota.
Are magic mushrooms ("shrooms") legal in Minnesota?
"Magic mushrooms" and "shrooms" are common names for fungi that contain psilocybin, and this entry states the law on psilocybin itself, which some laws treat separately from the fungus. Psilocybin has mixed legal status in Minnesota.
Read the law
Psychedelic Medicine Task Force final report (Jan 2025) recommending decriminalization and a regulated therapeutic program. Minnesota Laws 2026, chapter 123 (S.F. 4401), signed May 26, 2026, section 116: requires the Office of Cannabis Management to publish and submit a Psilocybin Therapeutic Use Program Report by January 15, 2027, with recommendations on administering a program for adults 21 and older with qualifying medical conditions under facilitator supervision at a treatment facility. HF 2906 (psilocybin therapeutic use program, Schedule I to IV reclassification) and HF 2699 (decriminalization, 21+) introduced 2025; neither enacted.1
Sources
This entry's status is checked against the primary sources below, and the methodology explains how each entry is graded for confidence.
- 1.revisor.mn.gov (opens in new tab) · revisor.mn.gov
- 2.revisor.mn.gov (opens in new tab) · revisor.mn.gov
This entry is for information only and is not legal or medical advice. Laws change, and enforcement can differ from the letter of the law, so check the current position against the primary sources above before relying on it.
Changes to this record
3 changes on file, the latest on . Show allHide
Every change we have made to this record, dated, corrections included. Nothing changes silently.
Minnesota did enact psilocybin language in 2026 after all. It is not access: a cannabis act signed in May requires the state to publish a report by 15 January 2027 on how a psilocybin therapeutic use program could work. We had recorded that no psilocybin provision passed.
Minnesota's record now lists three more psilocybin bills from the 2026 session. None passed, and the session adjourned in May 2026.
Minnesota's mixed status was confirmed. HF 2906 had moved further than the entry showed, clearing a House committee in March 2026, but it was still unenacted when the biennium closed.
Psilocybin Media Group. "Minnesota: psilocybin legal status." The Psilocybin Record, accession US-MN-001, version of 23 Aug 2026. https://psilocybinlegalization.com/record/minnesota